Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

pembrolizumab 29Cisplatin 18Nivolumab 14Carboplatin 14Paclitaxel 13Cyclophosphamide 13Radiation 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Magnetic Resonance Spectroscopy 9Cytarabine 9Vincristine 8Radiosurgery 8Docetaxel 8Bevacizumab 8Pemetrexed 7Metformin 7Leucovorin 7Injections 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Letrozole 6Irinotecan 6Ipilimumab 6Gemcitabine 6Dexamethasone 6venetoclax 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Panzyga × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡